Material Name: Tolterodine Tartrate Tablets

Trade Name: Detrol®, Detrusitol®
Chemical Family: Mixture
Intended Use: Pharmaceutical product used for overactive bladder

2. HAZARDS IDENTIFICATION

Appearance: White tablets
Signal Word: WARNING

Statement of Hazard: Suspected of damaging the unborn child.

Additional Hazard Information:
- **Short Term:** Accidental ingestion may cause effects similar to those seen in clinical use.
- **Long Term:** Repeat-dose studies in animals have shown a potential to cause adverse effects on fetus.

Known Clinical Effects: May cause effects similar to those seen in clinical use including dry mouth, blurred vision, constipation, and upset stomach.

**EU Indication of danger:** Toxic to Reproduction: Category 3

**EU Hazard Symbols:**

![Xn]

**EU Risk Phrases:** R63 - Possible risk of harm to the unborn child.

**Australian Hazard Classification (NOHSC):** Hazardous Substance. Non-Dangerous Goods.

**Note:** This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tolterodine L-Tartrate</td>
<td>124937-52-6</td>
<td>Not Listed</td>
<td>Xn;R63 N;R51/53</td>
<td>1 mg or 2 mg ***</td>
</tr>
<tr>
<td>Silica colloidal, Ph. Eur.</td>
<td>112945-52-5</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Titanium dioxide</td>
<td>13463-67-7</td>
<td>236-675-5</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Microcrystalline cellulose</td>
<td>9004-34-6</td>
<td>232-674-9</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>209-150-3</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact: Flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.

Skin Contact: Wash skin with soap and water. If irritation occurs or persists, get medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Emits toxic fumes of carbon monoxide and nitrogen oxide.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls. Refer to Section 12 - Ecological Information, for information on potential effects on the environment.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Tolterodine L-Tartrate

Pfizer OEL TWA-8 Hr: 25µg/m³

Silica colloidal, Ph. Eur.

Austria OEL - MAKs 4 mg/m³

Titanium dioxide

ACGIH Threshold Limit Value (TWA) 10 mg/m³

Australia TWA 10 mg/m³

Austria OEL - MAKs 5 mg/m³

Belgium OEL - TWA 10 mg/m³

Bulgaria OEL - TWA 10.0 mg/m³

Denmark OEL - TWA 6 mg/m³

Estonia OEL - TWA 5 mg/m³

France OEL - TWA 10 mg/m³

Greece OEL - TWA 10 mg/m³

Ireland OEL - TWAs 10 mg/m³

4 mg/m³

Latvia OEL - TWA 10 mg/m³

Lithuania OEL - TWA 5 mg/m³

OSHA - Final PELS - TWAs: 15 mg/m³

Poland OEL - TWA 10.0 mg/m³

Portugal OEL - TWA 10 mg/m³

Romania OEL - TWA 10 mg/m³

Spain OEL - TWA 10 mg/m³

Sweden OEL - TWAs 5 mg/m³
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Analytical Method:
Analytical method available for tolterodine. Contact Pfizer Inc for further information.

Engineering Controls:
Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls:
Refer to specific Member State legislation for requirements under Community environmental legislation.

Personal Protective Equipment:
Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

- Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
- Eyes: Wear safety glasses or goggles if eye contact is possible.
- Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
- Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

- Physical State: Tablet
- Color: White
- Molecular Formula: Mixture
- Molecular Weight: Mixture

10. STABILITY AND REACTIVITY

- Chemical Stability: Stable under normal conditions of use.
- Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
- Incompatible Materials: As a precautionary measure, keep away from strong oxidizers.
### 11. TOXICOLOGICAL INFORMATION

**General Information:** The information included in this section describes the potential hazards of the individual ingredients.

**Acute Toxicity: (Species, Route, End Point, Dose)**

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Species</th>
<th>Route</th>
<th>End Point</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Titanium dioxide</td>
<td>Rat</td>
<td>Oral</td>
<td>LD50</td>
<td>&gt;2000 mg/kg</td>
</tr>
<tr>
<td></td>
<td>Rat</td>
<td>Subcutaneous</td>
<td>LD50</td>
<td>50 mg/kg</td>
</tr>
<tr>
<td></td>
<td>Rat</td>
<td>Inhalation</td>
<td>LC50</td>
<td>&gt;2000 mg/m³</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Species</th>
<th>Route</th>
<th>End Point</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microcrystalline cellulose</td>
<td>Rat</td>
<td>Oral</td>
<td>LD50</td>
<td>&gt;5000 mg/kg</td>
</tr>
<tr>
<td></td>
<td>Rabbit</td>
<td>Dermal</td>
<td>LD50</td>
<td>&gt;2000 mg/kg</td>
</tr>
</tbody>
</table>

**Titanium dioxide**

- Rat Oral LD50 > 7500 mg/kg
- Rat Subcutaneous LD 50 50 mg/kg

**Stearic acid**

- Rat Oral LD50 > 4640 mg/kg
- Rabbit Dermal LD50 > 5000 mg/kg

**Hydroxypropyl methylcellulose**

- Rat Oral LD50 > 10,000 mg/kg

**Tolterodine L-Tartrate**

- Mouse Oral LD 50 > 200 mg/kg

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

**Irritation / Sensitization: (Study Type, Species, Severity)**

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Study Type</th>
<th>Species</th>
<th>Severity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microcrystalline cellulose</td>
<td>Skin</td>
<td>Rabbit</td>
<td>Non-irritating</td>
</tr>
<tr>
<td></td>
<td>Eye</td>
<td>Rabbit</td>
<td>Non-irritating</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stearic acid</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin</td>
</tr>
<tr>
<td>Eye</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tolterodine L-Tartrate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin Irritation</td>
</tr>
<tr>
<td>Skin Sensitization - GPMT</td>
</tr>
</tbody>
</table>

**Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)**

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Duration</th>
<th>Species</th>
<th>Route</th>
<th>Dose</th>
<th>End Point</th>
<th>Target Organ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stearic acid</td>
<td>30 Week(s)</td>
<td>Rat</td>
<td>Oral</td>
<td>300 ppm</td>
<td>LOAEL</td>
<td>Adipose tissue</td>
</tr>
<tr>
<td>Tolterodine L-Tartrate</td>
<td>26 Week(s)</td>
<td>Mouse</td>
<td>Oral</td>
<td>10 mg/kg/day</td>
<td>NOAEL</td>
<td>None identified</td>
</tr>
<tr>
<td></td>
<td>52 Week(s)</td>
<td>Dog</td>
<td>Oral</td>
<td>0.5 mg/kg/day</td>
<td>NOAEL</td>
<td>None identified</td>
</tr>
</tbody>
</table>
11. TOXICOLOGICAL INFORMATION

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

**Tolterodine L-Tartrate**
- Reproductive & Fertility-Females: Mouse Oral 20 mg/kg/day NOAEL No effects at maximum dose
- Reproductive & Fertility-Males: Mouse Oral 30 mg/kg/day NOAEL No effects at maximum dose
- Embryo / Fetal Development: Mouse Oral 20 mg/kg/day NOAEL Embryotoxicity, Teratogenic

**Genetic Toxicity: (Study Type, Cell Type/Organism, Result)**

- **Stearic acid**
  - In Vitro Bacterial Mutagenicity (Ames) Salmonella Negative
  - Unscheduled DNA Synthesis E. coli Negative

- **Tolterodine L-Tartrate**
  - Bacterial Mutagenicity (Ames) Salmonella, E. coli Negative
  - In Vivo Chromosome Aberration Human Lymphocytes Negative
  - In Vivo Micronucleus Mouse Negative

**Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))**

- **Stearic acid**
  - 26 Week(s) Rat Subcutaneous 0.5 mg/kg/week NOAEL Not carcinogenic
  - 52 Week(s) Mouse Subcutaneous 0.05 mg/kg/week LOAEL Tumors

- **Tolterodine L-Tartrate**
  - Not specified Mouse Oral 30 mg/kg/day Maximally Tolerated Dose Not carcinogenic

**Carcinogen Status:**
- None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

- **Titanium dioxide**
  - IARC: Group 2B (Possibly Carcinogenic to Humans)
  - OSHA: Listed

- **Silica colloidal, Ph. Eur.**
  - IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

**Environmental Overview:**
This mixture contains material that is toxic to aquatic life. See Aquatic toxicity data of the active ingredient, below:

**Aquatic Toxicity: (Species, Method, End Point, Duration, Result)**

- **Tolterodine L-Tartrate**
  - *Daphnia magna* (Water Flea) OECD LC50 48 Hours 1.7 mg/L
  - *Pseudokirchneriella subcapitata* (Green Alga) EC50 72 Hours 20 mg/L
13. DISPOSAL CONSIDERATIONS

**Waste Treatment Methods:** Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

**EU Symbol:** Xn
**EU Indication of danger:** Toxic to Reproduction: Category 3
**EU Risk Phrases:** R63 - Possible risk of harm to the unborn child.

**EU Safety Phrases:**
- S22 - Do not breathe dust.
- S36/37 - Wear suitable protective clothing and gloves.

**OSHA Label:**
WARNING
Suspected of damaging the unborn child.

**Canada - WHMIS: Classifications**
**WHMIS hazard class:** Class D, Division 2, Subdivision A

Sodium starch glycolate
Inventory - United States TSCA - Sect. 8(b)
Present
15. REGULATORY INFORMATION

Australia (AICS): Present
Silica colloidal, Ph. Eur.
  Australia (AICS): Present
Titanium dioxide
  Inventory - United States TSCA - Sect. 8(b) Present
  Australia (AICS): Present
  EU EINECS/ELINCS List 236-675-5
Dibasic calcium phosphate, dihydrate USP
  Australia (AICS): Present
Stearic acid
  Inventory - United States TSCA - Sect. 8(b) Present
  Australia (AICS): Present
  EU EINECS/ELINCS List 200-313-4
Hydroxypropyl methylcellulose
  Inventory - United States TSCA - Sect. 8(b) Present
  Australia (AICS): Present
  Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 4
Microcrystalline cellulose
  Inventory - United States TSCA - Sect. 8(b) Present
  Australia (AICS): Present
  EU EINECS/ELINCS List 232-674-9
Magnesium stearate
  Inventory - United States TSCA - Sect. 8(b) Present
  Australia (AICS): Present
  EU EINECS/ELINCS List 209-150-3

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R63 - Possible risk of harm to the unborn child.
R51/53 - Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

Data Sources: Pfizer proprietary drug development information. Safety data sheets for individual ingredients. Publicly available toxicity information.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 4 - First Aid Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 10 - Stability and Reactivity. Updated Section 11 - Toxicology Information. Updated Section 13 - Disposal Considerations.

Prepared by: Product Stewardship Hazard Communication
  Pfizer Global Environment, Health, and Safety Operations
Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet